ADOCIA disclosed its total number of outstanding shares and voting rights as of June 30, 2026, reporting 20,053,056 shares, 21,211,032 theoretical voting rights and 21,165,333 exercisable voting rights. The company said 245,000 new shares were issued during the month in connection with the financing line established with Vester Finance, whose main characteristics were described in an April 21, 2026 press release. Under French market rules, theoretical voting rights are used to assess threshold crossings and include all shares attached to voting rights, including those whose voting rights are suspended, while exercisable voting rights exclude suspended voting rights. ADOCIA described itself as a clinical-stage biopharmaceutical company focused on developing therapeutic solutions for diabetes and obesity. It said its pipeline is built on four proprietary technology platforms: BioChaperone for peptide formulation and combinations, AdOral for oral peptide delivery, AdoShell for immunoprotective biomaterials in cell transplantation, and AdoXLong for long-acting peptides.